Clinical Trial: Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy

U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07824505) titled 'Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy' on Sept. 11.

Brief Summary: Indication: Patients with advanced recurrent or metastatic thymic carcinoma. Phase IIa (China only):Approximately 6 patients. Phase IIb (China only):Approximately 54 patients.

Study Start Date: Aug. 16, 2018

Study Type: INTERVENTIONAL

Condition: Advanced Thymic Carcinoma

Intervention: DRUG: lucitanib 15 mg QD

Phase IIa: The investigational product will be orally administrated when fasting at dose level of lucitanib 15 mg, QD, 3 weeks on and 1 week off

DRUG: lucitanib 10 mg QD

Phase IIb: The investigational product ...